crizotinib and Esophageal-Diseases

Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

Topics: Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Endoscopes; Esophageal Diseases; Female; Humans; Lung Neoplasms; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Tomography, X-Ray Computed; Treatment Outcome; Ulcer

Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Esophageal Diseases; Esophagoscopy; Female; Humans; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Ulcer

This report describes esophageal ulcer as a novel adverse event associated with crizotinib therapy. Although crizotinib is generally well tolerated, physicians should be aware of the possibility of this adverse event.

Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Endoscopy, Digestive System; Esophageal Diseases; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Ulcer